Get the Stockscreener App
0.1647
10.73%
-0.0198
After Hours:
.17
0.0053
+3.22%
Bioatla Inc stock is traded at $0.1647, with a volume of 3.78M.
It is down -10.73% in the last 24 hours and down -47.66% over the past month.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.
See More
Previous Close:
$0.1845
Open:
$0.1831
24h Volume:
3.78M
Relative Volume:
1.59
Market Cap:
$10.55M
Revenue:
-
Net Income/Loss:
$-123.46M
P/E Ratio:
-0.0636
EPS:
-2.59
Net Cash Flow:
$-104.11M
1W Performance:
-13.36%
1M Performance:
-47.66%
6M Performance:
-55.50%
1Y Performance:
-60.77%
1-Day Range:
$0.1485
$0.1899
1-Week Range:
$0.1485
$0.2238
52-Week Range:
$0.14
$1.43
Bioatla Inc Stock (BCAB) Company Profile
Name
Bioatla Inc
Sector
Industry
Phone
858-558-0708
Address
11085 TORREYANA ROAD, SAN DIEGO
Compare BCAB vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BCAB
Bioatla Inc
|
0.1647 | 11.82M | 0 | -123.46M | -104.11M | -2.59 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Bioatla Inc Stock (BCAB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-13-26 | Initiated | Rodman & Renshaw | Buy |
| Aug-13-25 | Downgrade | Citizens JMP | Mkt Outperform → Mkt Perform |
| Nov-13-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Sep-15-22 | Initiated | JMP Securities | Mkt Outperform |
| May-05-22 | Downgrade | Credit Suisse | Outperform → Neutral |
| Mar-21-22 | Initiated | H.C. Wainwright | Buy |
| Oct-15-21 | Resumed | BTIG Research | Buy |
| Jun-28-21 | Initiated | ROTH Capital | Buy |
| May-05-21 | Resumed | Credit Suisse | Outperform |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Jan-11-21 | Initiated | BTIG Research | Buy |
| Jan-11-21 | Initiated | Credit Suisse | Outperform |
| Jan-11-21 | Initiated | JP Morgan | Overweight |
| Jan-11-21 | Initiated | Jefferies | Buy |
View All
Bioatla Inc Stock (BCAB) Latest News
12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga
BioAtla Sets March Virtual Vote on Internal Merger Plan - TipRanks
BioAtla (BCAB) seeks approval for 1‑for‑50 share conversion to support Nasdaq listing - Stock Titan
Bioatla Faces Nasdaq Delisting Review Amid Corporate Restructuring - AD HOC NEWS
Is BioAtla Inc. currently under institutional pressureQuarterly Risk Review & Technical Analysis for Trade Confirmation - mfd.ru
BioAtla to remain on Nasdaq during listing council review process By Investing.com - Investing.com India
BioAtla to remain on Nasdaq during listing council review process - Investing.com
BioAtla Faces Nasdaq Review of Continued Listing Status - TipRanks
BioAtla Faces Nasdaq Delisting Review - TradingView
Why STMicroelectronics Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket - Benzinga
BioAtla to be suspended from Nasdaq after delisting determination By Investing.com - Investing.com Nigeria
BioAtla to be suspended from Nasdaq after delisting determination - Investing.com
BioAtla Faces Nasdaq Trading Suspension and Potential Delisting - TipRanks
BioAtla Received Notice of Delisting - TradingView
Activity Recap: Will BioAtla Inc benefit from AI trends2025 Biggest Moves & Precise Buy Zone Tips - baoquankhu1.vn
BioAtla sets merger plan after Nasdaq rule change affects reverse split vote By Investing.com - Investing.com South Africa
BioAtla sets merger plan after Nasdaq rule change affects reverse split vote - Investing.com Australia
BioAtla (BCAB) seeks approval for 1-for-50 share conversion and charter changes - stocktitan.net
BioAtla Pursues Share Consolidation Amid Nasdaq Compliance Dispute - TipRanks
Street Watch: What is the dividend yield of BioAtla IncGold Moves & Reliable Momentum Entry Alerts - baoquankhu1.vn
Is BioAtla Inc. a turnaround story2025 Biggest Moves & Verified Technical Trade Signals - mfd.ru
EPS Watch: Will BioAtla Inc stock hit new highs in YEARWeekly Profit Report & Smart Investment Allocation Tips - baoquankhu1.vn
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Aug Mood: Will BioAtla Inc stock hit new highs in YEAR2025 Earnings Impact & Real-Time Volume Analysis - baoquankhu1.vn
Aug Sectors: Is BioAtla Inc forming bullish engulfing patternsJuly 2025 Outlook & Weekly Chart Analysis and Guides - baoquankhu1.vn
Aug Chart Watch: What is the dividend yield of BioAtla IncWatch List & Technical Buy Zone Confirmations - baoquankhu1.vn
Whale Trades: Is BioAtla Inc forming bullish engulfing patternsJuly 2025 Price Swings & Risk Controlled Daily Plans - baoquankhu1.vn
What analysts say about BioAtla Inc. stockTrade Risk Assessment & Free Low Drawdown Momentum Trade Ideas - bollywoodhelpline.com
BioAtla stock slips premarket after early pop as investors weigh $40M SPV deal for phase 3 cancer trial - MSN
Aug Decliners: Can BioAtla Inc deliver consistent dividendsEarnings Overview Summary & Scalable Portfolio Growth Methods - baoquankhu1.vn
Big Money Moves: Should you buy the dip on BioAtla IncJuly 2025 Update & High Accuracy Trade Signal Alerts - baoquankhu1.vn
Brokerages Set BioAtla, Inc. (NASDAQ:BCAB) Target Price at $4.00 - Defense World
BioAtla faces Nasdaq delisting over share price rule - MSN
BioAtla (NASDAQ:BCAB) Coverage Initiated by Analysts at Rodman & Renshaw - Defense World
VIX Spike: Can BioAtla Inc deliver consistent dividendsJuly 2025 Review & Precise Entry and Exit Recommendations - baoquankhu1.vn
BioAtla Creates Super-Voting Share to Advance Reverse Split - The Globe and Mail
BioAtla stock initiated with Buy rating at Rodman & Renshaw - Investing.com
BioAtla stock initiated with Buy rating at Rodman & Renshaw By Investing.com - Investing.com India
Why BioAtla Inc. stock remains resilientJuly 2025 Gainers & Real-Time Buy Signal Notifications - Улправда
BioAtla, Inc.Common Stock (NQ: BCAB - FinancialContent
Is BioAtla Inc. stock undervalued vs historical averages2025 Big Picture & Consistent Growth Stock Picks - ulpravda.ru
Is BioAtla Inc. stock attractive for hedge funds2025 Volatility Report & Daily Stock Trend Reports - Улправда
Is BioAtla Inc. stock dividend yield sustainable2025 Stock Rankings & Entry Point Confirmation Alerts - Улправда
What risks investors should watch in BioAtla Inc. stockEarnings Risk Report & Fast Entry Momentum Trade Alerts - Улправда
How BioAtla Inc. stock performs in rising dollar environmentMarket Volume Summary & Short-Term Trading Alerts - Улправда
How rising interest rates impact BioAtla Inc. stock2025 EndofYear Setup & Free Community Consensus Stock Picks - ulpravda.ru
Will BioAtla Inc. stock maintain momentum in 2025Volatility Index Analysis & Low Cost Portfolio Growth - ulpravda.ru
After-Hours Biotech Rally: Alumis, Genelux, Bright Minds, Context Therapeutics Post Big Gains - RTTNews
Why GH Research Shares Are Trading Higher By 18%; Here Are 20 Stocks Moving Premarket - Benzinga
BioAtla, GATC Health Advance Ozuriftamab Vedotin Into Phase 3 OPSCC Trial Via SPV Deal - Voice Of HealthCare
BioAtla Stock Slips Premarket After Early Pop As Investors Weigh $40M SPV Deal For Phase 3 Cancer Trial - Asianet Newsable
Bioatla Inc Stock (BCAB) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.24%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):